How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,523 results for

Alpha Adrenergic Antagonist

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Treatment of Patients with Schizophrenia

medication, switching to another antipsychotic medication, adding a benzodiazepine medication, or adding a beta- adrenergic blocking agent. 14. APA recommends (1B) that patients who have moderate to severe or disabling tardive dyskinesia associated with antipsychotic therapy be treated with a reversible inhibitor of the vesicular monoamine transporter2 (VMAT2). Psychosocial Interventions 15. APA recommends (1B) that patients with schizophrenia who are experiencing a first episode of psychosis be treated

2020 American Psychiatric Association

122. Management of stable angina

revascularisation Completely revised 5.8.3 Enhanced counterpulsation Completely revised 5.8.4 Other approaches New 6 Stable angina and non-cardiac surgery Completely revised 6.1 Assessment prior to surgery Minor update 6.2 Perioperative revascularisation Minor update 6.3 Drug therapy in patients undergoing non-cardiac surgery Completely revised 6.3.1 Beta blockers Completely revised 6.3.2 Alpha 2 adrenergic receptor agonists Completely revised 6.3.4 Antiplatelet therapy Completely revised 6.3.5 Statins (...) that, following an Independent Review Panel Assessment: ranolazine (Ranexa®) is not recommended for use within NHS Scotland. Indication under review: as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta blockers and/or calcium antagonists). The submitting company did not present a sufficiently robust clinical and economic case to gain acceptance by the Independent Review Panel

2018 SIGN

123. Management of opioid use disorders: a national clinical practice guideline

. The recommendations in this guideline are based on the clin- ical evidence base regarding treatment approaches for opioid use disorder currently available in Canada, including oral opioid agonist treatment and antagonist pharmacotherapies, as well as withdrawal management strategies, residential treatment and psychosocial treatment interventions. The evidence base for pharmacotherapies not yet widely available in Canada, including long-acting and extended-release opioid antagonists, as well as injectable opioid (...) - tages of methadone and buprenorphine–naloxone are summarized in Table 2. Compared with use of a 2 -adrenergic agonists or psychosocial treatment alone, opioid agonist treatment with buprenorphine– naloxone or methadone has proven superior in terms of reten- tion in treatment, sustained abstinence from illicit opioid use, and reduced risk of morbidity and death. 21,25,37–40 Recent meta- analyses have found that buprenorphine–naloxone and metha- done were essentially equally efficacious across

2018 CPG Infobase

125. Management of Cardiovascular Diseases during Pregnancy Full Text available with Trip Pro

antagonist MRHD Maximum recommended human dose MRI Magnetic resonance imaging MS Mitral stenosis mWHO Modified World Health Organization NSTE-ACS Non-ST-elevation acute coronary syndrome NSTEMI Non-ST-elevation myocardial infarction NT-proBNP N-terminal pro B-type natriuretic peptide NYHA New York Heart Association OAC Oral anticoagulant OHSS Ovarian hyperstimulation syndrome OR Odds ratio PAH Pulmonary arterial hypertension PAP Pulmonary arterial pressure PCI Percutaneous coronary intervention PE (...) fms-like tyrosine kinase 1 STEMI ST-elevation myocardial infarction SVT Supraventricular tachycardia TAPSE Tricuspid annular plane systolic excursion TdP Torsade de pointes TGA Transposition of the great arteries TR Tricuspid regurgitation UFH Unfractionated heparin UPA Ulipristal acetate VKA Vitamin K antagonist VSD Ventricular septal defect VT Ventricular tachycardia VTE Venous thrombo-embolism WCD Wearable cardioverter-defibrillator WPW Wolff–Parkinson–White 1. Preamble Guidelines summarize

2018 European Society of Cardiology

126. Doxazosin

participants. (see ) Verified September 2016 by VA Office of Research and Development Sponsor (...) of cocaine dependence; however, both animal and human studies suggest that medications affecting the noradrenergic system can reduce cocaine craving and use. The investigators will study the effect of doxazosin , an alpha-1 adrenergic antagonist, in reducing cocaine use and anxiety symptoms among cocaine-dependent individuals. In addition, the investigators will identify genetic subpopulations (...) of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: An observational study. To explore the safety and efficacy of the selective 5-serotonin and norepinephrine reuptake inhibitor duloxetine hydrochloride and alpha-adrenergic receptor blocker (alpha-blocker) doxazosin mesylate-controlled tablets in the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS (...) ).In all, 150 patients were

2018 Trip Latest and Greatest

127. Latanoprost

of a new antiglaucoma drug lathanoprost, a 0.005% xalathane solution, prostaglandin F2 alpha analog, is studied. A single instillation of xalathane (...) Trial Perspektivy primeneniia analoga prostaglandina F2 al'fa latanoprosta v gipotenzivnoĭ terapii glaukomy. Russia (Federation) Vestn Oftalmol 0415216 0042-465X 0 Adrenergic beta-Antagonists 0 Ophthalmic Solutions 0 Parasympathomimetics 0 Prostaglandins F, Synthetic 01MI4Q9DI3 Pilocarpine 6Z5B6HVF6O latanoprost 817W3C6175 Timolol B7IN85G1HY Dinoprost (...) IM Adrenergic beta-Antagonists administration & dosage therapeutic use Chronic Disease Dinoprost analogs & derivatives Drug Therapy, Combination 1998 8. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Peeters A, Schouten JS, Severens JL, Hendrikse F, Prins MH, Webers CA Record Status

2018 Trip Latest and Greatest

128. Terazosin

Cooperative Studies Benign Prostatic Hyperplasia Study Group. 533-9 Men with benign prostatic hyperplasia can (...) be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared. We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs (...) Ravilla D RD eng Case Reports Letter India Indian J Ophthalmol 0405376 0301-4738 0 Adrenergic alpha-Antagonists 0 Platelet Aggregation Inhibitors 8L5014XET7 Terazosin XM03YJ541D 2007 11. Terazosin activated Pgk1 and Hsp90 to promote stress resistance 25383758 2014 12 18 2015 02 25 2017 02 20 1552-4469 11 1 2015 Jan Nature chemical biology Nat. Chem. Biol. Terazosin activates Pgk1 and Hsp90 to promote stress resistance. 19-25 10.1038/nchembio.1657 Drugs that can protect against organ damage

2018 Trip Latest and Greatest

129. Nifedipine

beta 2 -adrenergic-receptor agonists and better tolerated compared with beta 2 -adrenergic-receptor (...) agonists and magnesium sulfate in women with preterm labour. The review was generally well conducted, but the authors’ conclusions regarding magnesium sulphate may be too strong given the small number of trials included in the analyses. Authors' objectives To determine the efficacy and safety of nifedipine as a tocolytic agent in women with preterm labour. Searching MEDLINE, EMBASE, LILACS, Web (...) of this study was to compare the effectiveness of nifedipine versus indomethacin 2011 10. Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker ( nifedipine ) and an alpha-blocker (tam Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost

2018 Trip Latest and Greatest

130. Quinapril

-adrenergic signal transduction pathway (...) by the development of fulminant hypertension with cardiac hypertrophy. 2. Seven week old heterozygous TG(mREN2)27 rats were treated for 11 weeks with the AT1-receptor antagonist losartan (10 mg kg[-1]), the ACE-inhibitor quinapril (15 mg kg[-1]) and the direct vasodilator hydralazine (30 mg kg[-1]). Untreated TG and normotensive Sprague-Dawley rats (SD) served as controls. 3. TG(mREN2)27-rats were characterized by arterial hypertension (TG 194+/-3.2 mmHg vs SD (...) The purpose of this study is to compare the impact of two blood pressure lowering treatments (high dose quinapril 2006 3. Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles" Search for studies: Study Record Detail Effects of Quinapril 40 mg

2018 Trip Latest and Greatest

131. ESC/ESH Management of Arterial Hypertension Full Text available with Trip Pro

Rosuvastatin LDH Lactate dehydrogenase LDL-C LDL cholesterol LEAD Lower extremity artery disease LIFE Losartan Intervention For Endpoint reduction in hypertension LV Left ventricular LVH Left ventricular hypertrophy MAP Mean arterial pressure MI Myocardial infarction MR Magnetic resonance MRA Mineralocorticoid receptor antagonist MRI Magnetic resonance imaging MUCH Masked uncontrolled hypertension NORDIL Nordic Diltiazem NS Non-significant NT-proBNP N-terminal pro-B natriuretic peptide o.d. Omni die (every

2018 European Society of Cardiology

132. Nimodipine Enhances {alpha}2 Adrenergic Modulation of NMDA Receptor Via A Mechanism Independent of Ca++ Channel Blocking. Full Text available with Trip Pro

Nimodipine Enhances {alpha}2 Adrenergic Modulation of NMDA Receptor Via A Mechanism Independent of Ca++ Channel Blocking. To further understand alpha2 receptor signaling in the retina and the mechanisms that mediate ocular beneficial effects of brimonidine (an alpha2 agonist) and nimodipine (an L-type Ca(2+) channel blocker).The authors used in situ retinal ganglion cells (RGCs) in the isolated rat retina to characterize alpha2 modulation of NMDA receptor function and a rabbit retinal NMDA (...) -elicited currents in RGCs. This suppressive effect of brimonidine was substantially enhanced by background addition of nimodipine or isradipine, but not by diltiazem, verapamil, or cadmium. This effect of nimodipine was blocked by either a selective alpha2 antagonist, a cyclic adenosine monophosphate (cAMP) analogue, or an adenylate cyclase activator, indicating that nimodipine acts through the alpha2 receptor-G(alphai)-coupled pathway. Brimonidine protects RGCs in the rabbit excitotoxicity model

2010 Investigative Ophthalmology & Visual Science

133. Role of supraspinal and spinal {alpha}1-adrenergic receptor subtypes in micturition reflex in conscious rats. Full Text available with Trip Pro

Role of supraspinal and spinal {alpha}1-adrenergic receptor subtypes in micturition reflex in conscious rats. α(1)-Adrenergic receptor subtypes are widely distributed in the central nervous system and are involved in autonomic functions such as micturition. We investigated the presence and the role of supraspinal and/or spinal α(1)-adrenergic receptors in modulating the micturition reflex in conscious female Wistar rats. The expression of α(1)-adrenergic receptor subtypes in rat brain (...) and lumbosacral spinal cord was studied using RT-PCR. Continuous-infusion cystometrograms were obtained in conscious rats, and α(1)-adrenergic receptor antagonists were administered via intracerebroventricular or intrathecal routes. The mRNA expression of α(1A)-, α(1B)-, and α(1D)-adrenergic receptors was detected in rat brain (midbrain and pons) and lumbosacral spinal cord (dorsal and ventral parts of spinal cord). In addition, intracerebroventricular injection of the α(1)-adrenergic receptor antagonist

2010 American Journal of Physiology. Renal physiology

134. Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD

, in patients with glucose intolerance and diabetes. 35 Short-acting beta adrenergic agonists (SABAs) and short-acting muscarinic antagonists (SAMAs) are established treatments to relieve dyspnea and improve airflow obstruction during ECOPD, but the benefits of combining SABAs and SAMAs compared with using SABAs or SAMAs alone are unclear. 36 Long-acting bronchodilators and inhaled corticosteroids have historically only be used in stable COPD, but there is emerging evidence that an increase in dosage (...) Table 13. Comparison of oral mucolytics versus control, additional outcomes 24 Table 14. Comparison of inhaled corticosteroids with or without inhaled short- and long-acting bronchodilators versus placebo, critical outcomes 25 Table 15. Comparison of inhaled corticosteroids with or without inhaled short- and long-acting bronchodilators versus placebo, additional outcomes 25 Table 16. Comparison of inhaled antibiotics versus placebo 26 Table 17. Long-acting muscarinic antagonists versus placebo 26

2019 Effective Health Care Program (AHRQ)

135. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

are employed to treat LUTS attributed to BPH, including alpha- adrenergic antagonists (alpha-blockers), beta adrenergic agonists, 5-alpha- reductase inhibitors (5- ARIs), anticholinergics, vasopressin analogs, PDE-5 inhibitors, and phytotherapeutics, which can be utilized alone or in combination to take advantage of their different mechanisms of action. Conversely, there exist clinical scenarios when either conservative management , including life style changes (e.g., fluid restriction, avoidance

2019 American Urological Association

137. Management of Acute ST Segment Elevation Myocardial Infarction (STEMI) – (4th Edition)

SURGERY 91 11 RISK STRATIFICATION POST-STEMI 91-94 12 DURATION OF HOSPITALIZATION 95 13 SECONDARY PREVENTION 13.1 Non-Pharmacological Measures 13.1.1 Cessation of Smoking 13.1.2 Diet and Weight Control 13.1.3 Regular Exercise 13.2 Control of Cardiovascular Risk Factors 13.2.1 Glycaemic Control 13.2.2 Glycaemic Control 13.3 Pharmacotherapy 13.3.1 Anti-platelet Agents 13.3.2 Anti-coagulants 13.3.3 ß-blockers 13.3.4 Angiotensin Inhibitors/Angiotensin Receptor Blockers 13.3.5 Mineralocorticoid Antagonists (...) if given early are:  ACE-Is  ARBs if ACE-I intolerant  ß -blockers  Mineralocorticoid Receptor Antagonists (MRA)  High dose statins. Key Message #9: - Complications Post STEMI: • Important complications following STEMI are arrhythmias and heart failure. • Heart failure may be due to extensive myocardial damage or mechanical complications. • Chest pain post STEMI may be due to:  Reinfarction/Recurrent MI  Post infarct angina  Pericarditis  Non-cardiac causes such as gastritis Key Message #10

2019 Ministry of Health, Malaysia

138. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy Full Text available with Trip Pro

protein 20; VF = ventricular fibrillation; VT = ventricular tachycardia; SCN5A = sodium voltage-gated channel alpha subunit 5; TMEM43 = transmembrane protein 43. ---- | ---- Figure 4 Approach to understanding the common pathway and genetic variants in a patient with arrhythmogenic cardiomyopathy (ACM) according to the predominant ventricular dysfunction. See also Table 3 . ALVC = arrhythmogenic left ventricular cardiomyopathy; ARVC = arrhythmogenic right ventricular cardiomyopathy; BAG3 = BCL2 (...) associated athanogene 3; DSC2 = desmocollin-2; DSG2 = desmoglein-2; DSP = desmoplakin; FLNC = filamin-C; JUP = junction plakoglobin; KCNH2 = potassium voltage-gated channel subfamily H member 2; KCNQ1 = potassium voltage-gated channel subfamily Q member 1; LDB3 = LIM domain binding 3; LMNA = lamin A/C; NKX2-5 = NK2 homeobox 5; PKP2 = plakophilin-2; PLN = phospholamban; RBM20 = RNA binding motif protein 20; SCN5A = sodium voltage-gated channel alpha subunit 5; TMEM43 = transmembrane protein 43; TRPM4

2019 International Society for Heart and Lung Transplantation

140. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

are employed to treat LUTS attributed to BPH, including alpha-adrenergic antagonists (alpha-blockers), beta adrenergic agonists, 5-alpha- reductase inhibitors (5-ARIs), anticholinergics, vasopressin analogs, PDE-5 inhibitors, and phytotherapeutics, which can be utilized alone or in combination to take advantage of their different mechanisms of action. Conversely, there exist clinical scenarios when either conservative management , including life style changes (e.g., fluid restriction, avoidance (...) of renal deterioration if inadequately treated on medication. Long standing BOO from BPH can progress to incomplete bladder emptying, bilateral hydroureteronephrosis, and ultimately acute and/or chronic renal insufficiency. Although transient urethral catheterization with concomitant medical therapy using an alpha adrenergic antagonist can be considered, it is unlikely that the latter will adequately ameliorate the obstructive process to sufficiently prevent further upper urinary tract deterioration

2019 American Urological Association

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>